Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.

ABSTRACT: Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patients with high risk of relapse, is the key element in management in the initial stages. However, despite the availability of aggressive multidisciplinary treatments, advanced resectable OCSCC carries poor prognosis; only half of the patients are disease-free 5 years after the surgery. Immunotherapy based on the use of immune checkpoint inhibitors has been proven to be effective in a wide variety of tumours, including recurrent and metastatic HNSCC. These positive results resulted in investigations

SUBMITTER: Gutierrez Calderon V 

PROVIDER: S-EPMC7905482 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature